Curzion Pharmaceuticals is developing a late-stage small molecule to treat fibrotic conditions, where significant unmet needs exist. The safety and efficacy of its in-licensed lead development candidate have been demonstrated in prior mid-stage clinical studies. RiverVest was a founder of Curzion.

Acquired by Horizon Therapeutics in April 2020.